

Paola Ulivi (Italy)

Paola Ulivi has degrees in Medical Biotechnology (2000) and Molecular and Cellular Biology (2009), a Masters Degree in Pharmacology (2006) and a PhD in Pharmacological and Toxicological Sciences (2014). She was a researcher in the Biological Laboratory of the Department of Medical Oncology, Morgagni-Pierantoni Hospital, Forlì, from 2001 to 2008, and since 2008 she has worked at Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, as senior researcher. She is specialized in the area of molecular biology and, in particular, in the identification of molecular alterations that are responsible for sensitivity or resistance of solid tumors to targeted therapy. Dr. Ulivi is currently Head of the "Biomarkers and Personalized Medicine" research group in the Biosciences Laboratory of IRST-IRCCS, coordinating several research projects in the field of personalized treatment of lung cancer and gastrointestinal tract tumors. She is in charge of all the activities of Molecular Diagnostics in the Biosciences Laboratory of IRST-IRCCS. Dr. Ulivi is also the coordinating biologist in the Gruppo di Oncologia Polmonare di Area Vasta (GOPAV)", an interdisciplinary group of Medical Oncology Units in the wide catchment area of Romagna (Area Vasta Romagna, AVR) dedicated to Thoracic Oncology. The group has been operating since 2010 and is currently conducting several translational research projects. She is author of about seventy scientific articles published in international and indexed journals, of which more than twenty as first or last author. Finally, she has given about thirty oral presentations, many of these on lung cancer, at national and international conferences.

Best publications in the last five years

1. Impact of TP53 Mutations on Outcome in EGFR-Mutated Patients Treated with First-Line Tyrosine Kinase Inhibitors. Canale M, Petracci E, Delmonte A, Chiadini E, Dazzi C, Papi M, Capelli L, Casanova C, De Luigi N, Mariotti M, Gamboni A, Chiari R, Bennati C, Calistri D, Ludovini V, Crinò L, Amadori D, Ulivi P. Clin Cancer Res. 2016 Oct 25
2. Non-Invasive Methods to Monitor Mechanisms of Resistance to Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer: Where Do We Stand? Ulivi P. Int J Mol Sci. 2016 Jul 22;17(7).
3. Nonsquamous, Non-Small-Cell Lung Cancer Patients Who Carry a Double Mutation of EGFR, EML4-ALK or KRAS: Frequency, Clinical-Pathological Characteristics, and Response to Therapy. Ulivi P, Chiadini E, Dazzi C, Dubini A, Costantini M, Medri L, Puccetti M, Capelli L, Calistri D, Verlicchi A, Gamboni A, Papi M, Mariotti M, De Luigi N, Scarpi E, Bravaccini S, Turolla GM, Amadori D, Crinò L, Delmonte A. Clin Lung Cancer. 2016
4. miRNAs as non-invasive biomarkers for lung cancer diagnosis. Ulivi P, Zoli W. Molecules. 2014 Jun 17;19(6):8220-37
4. Peripheral Blood miR-328 Expression as a Potential Biomarker for the Early Diagnosis of NSCLC. Ulivi P, Foschi G, Mengozzi M, Scarpi E, Silvestrini R, Amadori D, Zoli W. Int J Mol Sci. 2013 May 16;14(5):10332-42
5. Role of quantitative and qualitative characteristics of free circulating DNA in the management of patients with non-small cell lung cancer. Ulivi P, Silvestrini R. Cell Oncol (Dordr). 2013 Dec;36(6):439-48